Business Wire

RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product

Share

RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/

RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege.

“The results from this ongoing international multicenter study are exceeding expectations, showcasing remarkable outcomes. We are profoundly optimistic and incredibly enthusiastic about what the future holds,” said Prof. Dr. med. Dent., Patrick Schmidlin, head of the Division of Periodontology at the University of Zurich, who serves as one of the investigators in RevBio’s pivotal clinical trial. “This breakthrough material promises to open a new chapter in dental care, redefining what is possible in regenerative dentistry.”

RevBio received regulatory and ethics committee approvals for five clinical sites consisting of one in Switzerland, two in Belgium, one in Spain, and one in the United Kingdom. Each site is expected to enroll between 12-25 patients for a total of approximately 75 patients. The investigators who are approved to enroll patients in this clinical trial are Prof. Dr. med. Dent., PhD, Patrick Schmidlin, head of the Department of Periodontology at the University of Zurich, Ana Castro, BDS MSc PhD, Clinical Head Department Periodontology at the Catholic University of Leuven, France Lambert, DDS, PhD, Professor and Head of Periodontology, Oral Surgery, and Implant Surgery at the University of Liege, Arturo Llobell, DDS, MS, a periodontist in private practice in Valencia, Spain, and Azim Malik, BDS, MFDS RCSEd, DipPCD RCSI, DClinDent, MPerio RCSEd, a periodontist and implant specialist in private practice in London, United Kingdom.

When teeth are extracted due to damage from traumatic injuries, tooth decay, or gum disease, the current standard of care consists of multiple staged surgical procedures to restore a patient’s dentition with prosthetic crowns supported by dental implants. Frequently, extraction sites are too large for dental implants to achieve primary stability through conventional mechanical engagement. Instead, patients must undergo a costly, complex, and lengthy process including a preliminary bone grafting surgery before receiving a dental implant. The use of TETRANITE to stabilize an unstable implant will allow for the immediate placement of dental implants which otherwise could not be placed until the initial bone graft has healed to form new bone. As a result, the TETRANITE® biomaterial will help reduce the duration and complexity of these dental implant procedures, lessen patient pain and recovery time, and reduce the overall cost of care thereby providing greater patient access for the treatment of tooth loss.

"The approval to conduct this pivotal clinical trial and the successful enrollment of the first 30 patients is a watershed moment for RevBio," said Alan Pollack, DDS, RevBio’s Senior Director of Dental Clinical Operations. “This clinical trial has the potential to significantly accelerate the timeframe when this promising bone adhesive technology can be used in the field of dentistry.”

About RevBio, Inc.

RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of TETRANITE®, a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's TETRANITE technology is not yet approved for commercial use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250306978603/en/

Contacts

Michael Tiedemann
mtiedemann@revbio.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spatial Corp. and Kawasaki Heavy Industries, Ltd Collaborate to Leverage Spatial Software Components to Power neoROSET Robot Programming19.3.2025 00:00:00 EET | Press release

Spatial Corp., the leading 3D software development toolkit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, and Kawasaki Heavy Industries, Ltd today announced their collaboration to leverage Spatial Software Development Kits (SDKs) in the development of neoROSET, Kawasaki next-generation offline robot programming tool. With Spatial, Kawasaki Heavy Industries, Ltd. benefited from SDK technological excellence as well as expertise to develop neoROSET, its advanced industrial robot programming software designed to simplify and optimize robotic systems assessment and construction. Key Spatial SDKs used in neoROSET include: CGM Modeler, a state-of-the-art 3D modeling kernel 3D InterOp, a robust data translation library enabling seamless data import and export in major formats HOOPS Visualize, a high-performance graphics library offering state-of-the-art visualization capabilities for engineering applications AGM, a comprehensive 3D applicati

NetApp Storage Now Validated for NVIDIA DGX SuperPOD, NVIDIA Cloud Partners, and NVIDIA-Certified Systems18.3.2025 22:00:00 EET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that NVIDIA has validated high-performance NetApp enterprise storage systems with NetApp ONTAP® for environments powering AI training and inferencing. For the first time, with NetApp, customers can now get the benefits of validated configurations and architectures for NVIDIA—including NVIDIA DGX SuperPOD, NVIDIA Cloud Partners, and NVIDIA-Certified Storage—combined with the rich and mature data management services in NetApp ONTAP critical for building AI factories. These certifications ready NetApp to tap the NVIDIA AI Data Platform reference design for NetApp ONTAP to advance storage infrastructure with AI agents for reasoning model inference workloads, powered by NVIDIA accelerated computing, networking, and software. “NetApp and NVIDIA are longstanding technology partners, jointly serving hundreds of customers for AI model training and inferencing,” said Jonsi Stefansson, Senior Vice President and C

NetApp Fuels Future of Agentic AI Reasoning Solutions with NVIDIA AI Data Platform18.3.2025 22:00:00 EET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it is advancing the state of the art in agentic AI with intelligent data infrastructure that taps the NVIDIA AI Data Platform reference design. By collaborating with NVIDIA, NetApp is enabling businesses to better leverage their data to fuel AI reasoning inference. In the era of intelligence, businesses need to rethink their data strategies to turn rapidly growing data estates into competitive assets that empower them to agilely navigate their business environment. By adopting an Intelligent Data Infrastructure framework, businesses will be able to operate under a unified vision that integrates metadata cataloging, automation, and hybrid cloud capabilities to eliminate siloes and deliver actionable insights at every stage of the AI pipeline. Together, NetApp ONTAP® and the NVIDIA AI Data Platform enable businesses to navigate the era of intelligence by building distributed systems that unlock the full

Outseer Launches Platformized Behavioral Biometrics Delivering Unmatched Defense in Depth18.3.2025 21:52:00 EET | Press release

Outseer, a recognized leader in authentication and fraud prevention for digital banking and 3-D Secure (3DS) transactions, announced its platform-native Behavioral Biometrics capability today. The addition of platformized Behavioral Biometrics introduces another layer of defense that continuously analyzes user interactions to detect anomalies in real time. Building on its rich RSA® heritage (formerly RSA Fraud & Risk Intelligence™), Outseer has enhanced its platform to meet today’s dynamic threat landscape. As fraud evolves—spurred by the digitization of payments, the spread of personal data across the dark web, the growing threat of scams and authorized fraud, as well as advancements like GenAI—Outseer’s multi-signal risk engine, leveraging sophisticated machine learning algorithms and AI, sets a new standard for continuous, unified protection. “Our customers are facing rising authorized and unauthorized fraud threats in digital banking and 3DS transactions, requiring fraud solutions

Ravenna Becomes the First Colourblind-Friendly City in Italy: Event and New EnChroma Glasses Donation18.3.2025 18:29:00 EET | Press release

Tomorrow, March 19, 2025, at 4:30 PM, the conference "How Colourblind People See" will be held at the Martini Hall of MAR – Ravenna’s Museum of Art. This event is dedicated to raising awareness about colour blindness and the challenges of colour perception. Speakers will include Stefano De Pietro, President of the Italian Association "How Colourblind People See", and Sandor Breznay, President of the Breznay-Ganoczy Foundation (Agno, Switzerland) and the Paolina Brugnatelli Foundation (Milan). Colour blindness affects approximately 1 in 12 men and 1 in 200 women, with over 300 million people worldwide experiencing this condition—2.5 million in Italy. While those with normal colour vision can distinguish over a million shades, individuals with colour vision deficiency see only about 10% of those hues. As a result, colours may appear dull or even indistinguishable. This initiative aims to increase public awareness and make cultural and educational experiences more accessible for those wit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye